Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-२.३१%
१,०४१.५३
-२४.६८
-२.३१%
१,०६६.२११,०६४.९४१,०६४.९४१,०३८.७७
SIXC
Communications
SIXC
Communications
SIXC
-०.९७%
६०५.२६
-५.९०
-०.९७%
६११.१६६११.१६६१२.२५६०४.७८
SIXE
Energy
SIXE
Energy
SIXE
+१.०१%
१,२८२.७४
+१२.८१
+१.०१%
१,२६९.९३१,२७३.१६१,२८७.५८१,२६२.६९
SIXI
Industrials
SIXI
Industrials
SIXI
-१.१७%
१,७००.२७
-२०.१४
-१.१७%
१,७२०.४११,७१७.३९१,७१७.३९१,६९४.४७
SIXM
Financials
SIXM
Financials
SIXM
-१.२३%
६२९.३१
-७.८२
-१.२३%
६३७.१३६३७.४०६३७.७४६२८.८३
SIXR
Staples
SIXR
Staples
SIXR
+०.१८%
८६७.८३
+१.५८
+०.१८%
८६६.२५८६५.७७८७४.१२८५८.७२
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+०.४३%
२१५.५७
+०.९३
+०.४३%
२१४.६४२१४.६४२१६.०८२१३.४९
SIXT
Technology
SIXT
Technology
SIXT
-०.६६%
३,४८७.८७
-२३.२६
-०.६६%
३,५११.१३३,४८१.०७३,५२७.५९३,४४०.२०
SIXU
Utilities
SIXU
Utilities
SIXU
+०.९९%
८९५.७२
+८.८०
+०.९९%
८८६.९२८८५.२३८९६.८३८८१.७४
SIXV
Health care
SIXV
Health care
SIXV
+१.०९%
१,४८६.४७
+१५.९८
+१.०९%
१,४७०.४९१,४७०.६८१,४९४.४२१,४६२.१६
SIXY
Discretionary
SIXY
Discretionary
SIXY
-१.१२%
२,३२३.५७
-२६.२०
-१.१२%
२,३४९.७७२,३३२.१७२,३३२.१७२,३०७.४३
GMAB:NASDAQ
Genmab A/S - ADR
US$ २५.६८
-२.६२%
(-०.६९) 1D
US$ २५.६५
-०.१२% (-०.०३०)
Pre-market
Closed: मे १९, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GMAB...
Open
US$ २५.६९
High
US$ २५.९८
Low
US$ २५.५२
Mkt. cap
१५.९७ अरब
Avg. vol.
१९.०६ लाख
Volume
८७.२१ हजार
P/E ratio
१९.४५
52-wk high
US$ ३५.४३
52-wk low
US$ २०.१४
EPS
US$ १.३२
Beta
०.८६
Shares outstanding
६२.३५ करोड
No. of employees
३ हजार
News stories
From sources across the web
Profile
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US. Wikipedia
About Genmab A/S - ADR
CEOJan G. J. van de Winkel
Employees३.०९ हजार
Founded१९९९
Headquarters-
Sector-
Websitegenmab.com
Last report
२०२६ मे ७
Fiscal Period
Q1 2026
EPS / Est. (DKK)
- / DKK ८.२३
Revenue / Est. (DKK)
५.६९ अरब / ५.६५ अरब
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
२०२३ डिसेम्बर
२०२४ मार्च
२०२४ जुन
२०२४ सेप्टेम्बर
Revenue
४.६८ अरब
४.१४ अरब
५.४० अरब
५.५४ अरब
Cost of goods sold
-
-
-
२७.३० करोड
Cost of revenue
-
-
-
२७.३० करोड
Research and development expenses
-
-
-
२.२८ अरब
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
८६.५० करोड
Operating expense
-
-
-
३.१५ अरब
Total operating expenses
-
-
-
३.४२ अरब
Operating income
-
-
-
२.१२ अरब
Other non operating income
-
-
-
-
EBT including unusual items
-
-
-
१.७२ अरब
EBT excluding unusual items
-
-
-
१.५९ अरब
Income tax expense
-
-
-
४५.३० करोड
Effective tax rate
-
-
-
२६.३५%
Other operating expenses
-
-
-
-
Net income
-
-
-
१.२७ अरब
Net profit margin
-
-
-
२२.८५%
Earnings per share
९.६७
-
-
१९.८१
Interest and investment income
-
-
-
१६.२० करोड
Interest expense
-
-
-
-१.८० करोड
Net interest expenses
-
-
-
१४.४० करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
२.२० अरब
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more